Portal de investigación
Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Molica, Matteo
- Miralles, Gema
- Dillon, Richard
- Annunziata, Mario
- Basheer, Faisal
- Burgues, Juan Miguel Bergua
- Calmet, Ferran Vall-Llovera
- Campbell, Victoria
- Cetin, Denis
- Cimino, Gaetano
- Ciotti, Giulia
- Corbingi, Andrea
- De Fazio, Laura
- Erol, Hasim Atakan
- Federico, Vincenzo
- Gulu, Yasa Mutlu
- Malcorra, Amaia Balerdi
- Mariani, Sabrina
- Martelli, Maria Paola
- Mazzone, Carla
- Mule, Antonino
- Musuraca, Gerardo
- Khan, Anjum
- Norata, Mariana
- O'nions, Jenny
- Palumbo, Fanny
- Papayannidis, Cristina
- Piccioni, Annalina
- Rubi, Maria Teresa Olave
- Sanchez-Tovar, Jackeline
- Serin, Istemi
- Serrao, Alessandra
- Sevindik, Omur
- Sucato, Giuseppe
- Urbano, Marina Aurora
- Vetro, Calogero
- Vives, Susana
- Rossi, Marco
- Othman, Jad
- Perrone, Salvatore
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 1662-1663
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Molica,M,Miralles,G,Dillon,R,Annunziata,M,Basheer,F,Burgues,JMB,Calmet,FV et al. Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients. 67th Annual Meeting of the American-Society-of-Hematology (ASH). 2025. Orlando. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2025 p.p. 1662-1663.